Outcomes of Multidrug-Resistant Tuberculosis Treated With Bedaquiline or Delamanid
- Background: Since 1 September 2016, bedaquiline and delamanid have been administered for the treatment of patients with multidrug-resistant/rifampicin-resistant tuberculosis after the official approval in South Korea. This study aimed to assess and compare the final treatment outcomes of patients who received bedaquiline with those of patients who received delamanid.
Methods: This is a nationwide cohort study of patients with multidrug-resistant/rifampicin-resistant tuberculosis in whom bedaquiline or delamanid was administered from 1 September 2016 to 28 February 2018, after receiving the official approval in South Korea. Patients were classified into the bedaquiline and delamanid group according to the first used drug. We evaluated and compared the final treatment outcomes between the groups.
Results: During the study period, 284 patients with multidrug-resistant/rifampicin-resistant tuberculosis were approved to use bedaquiline or delamanid and 260 were included in the final analysis; 119 (45.8%) and 141 patients (54.2%) were classified into bedaquiline and delamanid groups, respectively. Among them, 30 patients (11.5%) exhibited additional resistance to second-line injectable drugs, 94 patients (36.2%) had additional resistance to fluoroquinolones, and 37 patients (14.2%) had resistance to both drugs. The overall treatment success rate was 79.2%. Initiation of bedaquiline rather than delamanid was not associated with treatment success (adjusted odds ratio, .671; 95% confidence interval, .350-1.285). Frequencies of adverse events were not significantly different between the 2 groups.
Conclusions: Initial choice of bedaquiline or delamanid did not make any significant difference in the final treatment outcome or the frequencies of adverse events among patients with multidrug-resistant/rifampicin-resistant tuberculosis.
Keywords: diarylquinolines; multidrug-resistant; nitroimidazoles; oxazole; tuberculosis.
ⓒ The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: email@example.com.
- 심태선; Doosoo Jeon; Hyeontaek Hwang; Hyungseok Kang; Jae-Joon Yim; Yong-Soo Kwon
- Issued Date
- diarylquinolines; multidrug-resistant; nitroimidazoles; oxazole; tuberculosis
- CLINICAL INFECTIOUS DISEASES
- Citation Volume
- Citation Number
- Citation Start Page
- Citation End Page
Appears in Collections:
- Medicine > Medicine
- Authorize & License
- Files in This Item:
Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.